Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.

Feifei WeiKoichi AzumaYoshiro NakaharaHaruhiro SaitoNorikazu MatsuoTomoyuki TagamiTaku KouroYuka IgarashiTakaaki TokitoTerufumi KatoTetsuro KondoShuji MurakamiRyo UsuiHidetomo HimuroShun HoraguchiKayoko TsujiKenta MurotaniTatsuma BanTomohiko TamuraYohei MiyagiTetsuro Sasada
Published in: Journal for immunotherapy of cancer (2023)
The CIRI model is highly accurate and reproducible in determining the patients with NSCLC who would benefit from anti-PD-1/PD-L1 therapy with prolonged OS and may aid in clinical decision-making before and/or at the early stage of treatment.